Antibiotic safety assessment

International Journal of Antimicrobial Agents

Volumn 21, Issue 3, 2003, Pages 215-221

  Rouveix, Bernard ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

Antibiotic side effects; Stereoisomers; Structure toxicity relationships; Toxicodynamics; Toxicokinetics

Indexed keywords

ANTIBIOTIC AGENT; ASTEMIZOLE; BETA LACTAM ANTIBIOTIC; BROMFENAC; DEXFENFLURAMINE; ENZYME; FELBAMATE; FLOSEQUINAN; GREPAFLOXACIN; MACROLIDE; MIBEFRADIL; OFLOXACIN; QUINOLONE DERIVATIVE; TEMAFLOXACIN; TERFENADINE; TROVAFLOXACIN;

CHEMICAL STRUCTURE; DNA MICROARRAY; DRUG METABOLISM; DRUG SAFETY; GENETIC ANALYSIS; METABOLITE; MOLECULAR BIOLOGY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STEREOCHEMISTRY; STEREOISOMERISM; TOXICITY TESTING;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; HUMANS; RISK FACTORS; SAFETY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037334424     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00354-0     Document Type: Review

References (34)

1. Lumley CE, Walker SR. Predicting the safety of medicines from animal toxicity tests. II. Rodents and non-rodents, Arch. Toxicol. 1987; (Suppl II):300-4.
2. Lumley C. Clinical toxicity: could it have been predicted? premarketing experience. Lumley C.E., Walker S.R. Animal toxicity studies. Their reference for man. 1990;49-57 Quay Publishing, Lancaster.
3. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. J. Am. Med. Assoc. 279:1998;1200-1205.
4. Demoly P., Messaad O., Benhamed S., et al. Les réactions immuno-allergiques d'origine médicamenteuses: données épidémiologiques et cliniques. Thérapie. 55:2000;13-19.
5. Lipsky B.A., Baker C.A. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis. 28:1999;352-364.
6. Stahlmann R., Lode H. Toxicity of quinolones. Drugs. 58:(suppl 2):1999;37-42.
7. Demoly P., Bousquet J., Godard P., Michel F.B. Actualités des allergies médicamenteuses issues des antibiotiques et médicaments anti-rétroviraux. Bull. Acad. Natle. Méd. 184:2000;33-46.
8. Sartori E., Delaforge M., Mansuy D. In vitro interaction of rat liver cytochrome P 450 with erythromycin, oleandomycin and erythralosamine derivatives. Biochem. Pharmacol. 38:1989;2061-2068.
9. Caron F., Bouaniche M., Delatour F., et al. B. Effects of two oral erythromycin ethylsuccinate formulations on the motility of the small intestine in human beings. Antimicrob. Agents Chemother. 40:1996;1796-1800.
10. Domalga J.M. Structure-activity and structure-side-effect relationship for the quinolone antibacterials. J. Antimicrob. Chemother. 33:1994;685-706.
11. Bryskier A., Chantot J.F. Classification and structure-activity relationships of fluoroquinolones. Drugs. 49:(suppl 2):1995;16-28.
12. Tillotson G.S. Quinolones: structure-activity relationship and future predictions. J. Med. Microbiol. 44:1996;320-324.
13. Percival A. Impact of chemical structure on quinolone potency, spectrum and side effects. J. Antimicrob. Chemother. 28:(suppl 2):1991;1-8.
14. Scott A.K. Stereoisomers and drug toxicity. The value of single isomer therapy. Drug Safety. 8:1993;149-159.
15. Hutt A.J., Tan S.C. Drug chirality and its clinical significance. Drugs. 52:(suppl 5):1996;1-12.
16. Hutt A.J., O'Grady J. Drug chirality: a consideration of the significance of the stereochemistry of antimicrobial agents. J. Antimicrobial. Chemother. 37:1996;7-32.
17. Pirmohamed M., Kitteringham N.R., Park B.K. The role of active metabolites in drug toxicity. Drug Safety. 11:1994;114-144.
18. Pirmohamed M., Madden S., Park B.K. Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism. Clin. Pharmacokinet. 31:1996;215-230.
19. Zuhlsdorf M.T. Relevance of pheno- and genotyping in clinical drug development. Int. J. Clin. Pharmacol. Ther. 36:1998;607-612.
20. Breckenridge A. A clinical pharmacologist's view of drug toxicity. Br. J. Clin. Pharmacol. 42:1996;53-58.
21. Rouveix B., Coulombel L., Aymard J.P., Chau F., Abel L. Amodiaquine induced agranulocytosis: évidence of a drug dependent antibody-mediated immune response and a toxic bone marrow depression. Br. J. Haematol. 71:1989;7-11.
22. + T cells in individuals allergic to sulfonamides, phenytoin and carbamazepin. J. Immunol. 155:1995;462-472.
23. Carr A., Vasak E., Munro V., Penny R., Cooper D.A. Immunohistochemical assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin. Exp. Immunol. 97:1994;260-265.
24. Kaminski N., Allard J., Heller R.A. Use of oligonucleotide arrays to analyze drug toxicity. Ann. New York Acad. Sci. 919:2000;1-8.
25. Ajayi F.O., Sun H., Perry J. Adverse drug reactions: a review of relevant factors. J. Clin. Pharmacol. 40:2000;1093-1101.
26. Knowles S.R., Uetrecht J., Shear N.H. Idiosyncratic drug reactions: the réactive metabolite syndromes. Lancet. 356:2000;1587-1591.
27. Park B.K., Kitteringham N.R., Powell H., Pirmohamed M. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology. 16:2000;39-60.
28. Sugiyama Y., Ito K., Tsuda M., Horii I. Future prospects for toxicokinetics: its ability to predict drug adverse events in humans. J. Toxicol. Sci. 21:1996;511-516.
29. Fisman D.N., Kaye K.M. Once-daily dosing of aminoglycoside antibiotics. Infect. Dis. Clin. North Am. 14:2000;475-487.
30. Ali M.Z., Goetz M.B. A meta-analysis of the relative efficacy and toxicity of single dosing versus multiple daily dosing aminoglycosides. Clin. Infect. Dis. 24:1997;796-809.
31. Bailey T.C., Little J.R., Littenberg B., Reichley R.M., Dunagan W.C. A meta-analysis of extend versus multiple daily dosing of aminoglycosides. Clin. Infect. Dis. 24:1997;786-795.
32. Barza M., Ioannidis J.P., Cappelleri J.C., Lau J. Single or multiple daily doses of aminoglycosides: a meta analysis. Br. Med. J. 312:1996;338-345.
33. Ribak M.J., Abate B.J., Kang L., Ruffing M.J., Lerner S.A., Drusano G.L. Prospective evaluation of the effect of an aminoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43:1999;1549-1555.
34. Jaillon P., Dupuis B., Dahan R. Etudes électrophysiologiques pré-cliniques et cliniques en vue de la prédiction d'un effet proarythmique (torsade de pointe) iatrogène. Thérapie. 52:1997;271-280.